RXST — RxSight, Inc.

RxSight (RXST) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $30.3 million, a decrease of 14% year-over-year (YoY) from $35.3 million and down 10% from $33.6 million in Q2 2025.
• LAL Revenue: $25.7 million from 26,045 Light Adjustable Lenses (LALs) sold, up 6% YoY but down 5% sequentially.
• LDD Revenue: $3.2 million from 25 Light Delivery Devices (LDDs) sold, down 69% YoY and 38% sequentially.
• Gross Margin: Improved to 79.9%, up from 71.4% YoY and 74.9% in Q2 2025.
• Net Loss: GAAP net loss of $9.8 million ($0.24 per share), compared to a loss of $6.3 million ($0.16 per share) in Q3 2024. Non-GAAP net loss was $1.7 million ($0.04 per share).
• Cash Position: $227.5 million in cash and short-term investments, unchanged from Q2 2025.

2. Strategic Updates and Business Highlights

• Strengthened commercial execution in the U.S. and initiated global expansion efforts, particularly in Asia and Europe.
• Launched new practice development programs (MasterClass and Elevate) aimed at enhancing clinical engagement and optimizing LAL workflow.
• Increased engagement with over 2,000 ophthalmologists, representing approximately 20% of U.S. cataract surgeons.
• Focused on expanding the installed base of LDDs and enhancing the number of LAL procedures performed by existing customers.
• Appointed an Executive Vice President of International to lead global expansion initiatives.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Narrowed to $125 million to $130 million, implying a YoY decline of 11% to 7%. Q4 revenue expected between $23 million and $28 million.
• Gross Margin Guidance: Increased to 76% to 77%, up from previous guidance of 72% to 74%.
• Operating Expenses: Expected to remain between $145 million and $155 million, reflecting a 7% to 14% increase YoY.
• Anticipated sequential growth in LAL procedures, with a focus on optimizing existing accounts rather than solely relying on new LDD placements.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Significant drop in both LDD sales and overall revenue compared to previous periods.
• Market Competition: Increased competition from new entrants in the premium IOL market, which could impact demand for LAL.
• Reimbursement Pressure: Anticipated decline in Medicare reimbursement rates for cataract surgery in 2026 may further drive demand for premium IOLs but could also intensify competition.
• Operational Adjustments: While the company is making strategic changes, the transition may take time to yield significant results, indicating potential short-term challenges.

5. Notable Q&A Insights

• Management emphasized the importance of LAL procedure volumes as a key metric for evaluating success and growth.
• The company is focusing on increasing the number of active surgeons and optimizing LAL sales among existing practices.
• Concerns were raised about the impact of new market entrants and declining reimbursement rates, but management believes the overall long-term demand for premium IOLs will remain strong.
• The potential for LAL adoption among post-refractive and LASIK patients was highlighted as a significant growth opportunity.
• Management reiterated their commitment to building a strong foundation for future growth through enhanced customer engagement and education initiatives.

Overall, RxSight is navigating a challenging market environment while focusing on strategic growth initiatives and improving operational efficiencies.